Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LACTYFERRIN Forte + ZINC Defense is a combination therapy consisting of liposomal bovine lactoferrin and liposomal zinc, developed by Sesderma Laboratories and investigated by Jose David Suarez, MD. Bovine lactoferrin is a multifunctional glycoprotein that acts as an ACE2 receptor blocker, potentially preventing the SARS-CoV-2 spike protein from binding to and entering host cells. The zinc component is intended to provide additional antiviral and immune-supportive effects. Both components are encapsulated in 100 nm nanoliposomes (phosphatidylcholine) to enhance bioavailability and stability. The combination was evaluated in a Phase 2 clinical trial for the treatment of non-hospitalized patients with mild to moderate COVID-19.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LACTYFERRIN Forte + ZINC Defense.